New cancer clinical trial: S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Published on: January 30, 2019 at 12:00PM
Condition:   Small Cell Lung Cancer Recurrent
Intervention:   Drug: S1/Anlotinib
Sponsor:   Taizhou Hospital
Not yet recruiting
http://bit.ly/2S4gnQc